PHASTAR Joins Oncology Development Programme (ODP2) to Accelerate Development of Novel Cancer Innovations
London, UK and Durham, NC – 08 December, 2022 – Phastar, a global specialist biometrics contract research organization (CRO), has joined Lean Life Science’s Oncology Development Programme (ODP2). The targeted programme aims to identify and accelerate novel oncology innovations into commercially-attractive assets by offering support to academics and early-stage companies.
In collaboration with top global pharma companies, Cancer Research UK’s Cancer Research Horizons, Manchester Cancer Research Centre (MCRC) and more than 20 specialist CROs, ODP2 aims to identify, de-risk and catalyse commercially viable UK-based innovations to improve diagnosis and treatment of cancer and accelerate the translation of emerging cancer research for patient benefit.
Phastar will be offering support from its biometrics experts, including statisticians, data scientists, data managers and programmers as part of the scheme. Its commitment to ODP2 mirrors its existing Phastar CARES programme – a comprehensive, corporate Environmental, Social, and Governance (ESG) strategy which offers pro bono support to charities.